Pharma BD Deal Intelligence
AstraZeneca acquired US biotech TeneoTwo (a TeneoBio spinout) to add its single clinical-stage asset, TNB-486 — a fully human CD19xCD3 bispecific T-cell engager for B-cell hematologic malignancies. The deal was structured as $100M upfront plus up to $805M in R&D milestones and up to $360M in commercial milestones (up to ~$1.27B total). Announced January 2022 and completed August 2022. Since the deal, AstraZeneca renamed the asset AZD0486 (INN surovatamig) and advanced it from Phase 1 to Phase 3: at ASH 2024, doses ≥2.4 mg produced a 96% overall response and 85% complete response with rapid MRD clearance in relapsed/refractory follicular lymphoma, with CRS in 45% of patients but all Grade 1. The pivotal Phase 3 SOUNDTRACK-F1 trial (NCT06549595) now tests surovatamig plus rituximab versus chemoimmunotherapy in previously untreated follicular lymphoma, with Phase 2 SOUNDTRACK-B running in relapsed/refractory NHL — validating the original bispecific T-cell-engager thesis.